IAS-Konferenz in Rio de
Janeiro: Slides and Posters
Gilead-initiated or Gilead-supported Abstracts AIDS 2026
Selected Gilead-initiated abstracts
| B/F/TAF QD | |
|---|---|
| Long-term efficacy and safety of B/F/TAF in children and adolescents with HIV-1 aged 2 to <18
years |
Natukunda_AIDS26_Oral_BVY_Peds_Final_15Jul26.pdf |
| Outcomes in treatment-experienced (TE) people with HIV (PWH) and detectable viremia switching to B/F/TAF
in routine clinical practice: 24-month (M) results from the BICSTaR study |
van_Welzen__B_AIDS26_Poster_TUPEB092_AIDS1356_Tx.pdf |
| Low incidence of treatment-emergent resistance to B/F/TAF under real-world adherence conditions among
people with HIV in the United States, 2018-2024 |
Levintow__S.N_AIDS26_Poster_TUPEB131_AIDS1395_Tx.pdf |
| Community HERO Treatment Survey: insights into rapid antiretroviral therapy initiation patterns and perceptions across a global population of people with HIV | Guillaume__X_AIDS26_Poster_WEPED313_AIDS2199_Tx.pdf |
| Community HERO Treatment Survey: perceptions on ageing across a global population of people with HIV |
Guillaume__X_AIDS26_Poster_WEPED317_AIDS2203_Tx.pdf |
| Community HERO treatment survey: stigma and barriers to and facilitators of treatment adherence across a
global population of people with HIV |
Guillaume__X_AIDS26_Poster_THPED275_AIDS0877_Tx.pdf |
| BIC/LEN QD | |
| Metabolic changes at 48 weeks in people with HIV and virologic suppression switching to single-tablet
BIC/LEN from complex antiretroviral regimens: Results from the Phase 3 ARTISTRY-1 trial |
Cassetti__I.L_AIDS26_Poster_TUPEB089_AIDS1353_Tx.pdf |
| Efficacy and safety of BIC/LEN single tablet regimen in virologically suppressed people with HIV aged
≥65 Years: Week 48 analysis of participants in the Phase 3 portion of ARTISTRY-1 |
Bloch__M_AIDS26_Poster_TUPEB096_AIDS1360_Tx.pdf |
| Pharmacokinetic data supporting the safety and efficacy of BIC/LEN in Phase 3 studies |
Arora__P_AIDS26_Poster_TUPEB094_AIDS1358_Tx.pdf |
| Increased treatment satisfaction and maintained health-related quality of life among people with HIV
switching to a BIC/LEN single-tablet regimen from complex regimens: Results from the Phase 3 ARTISTRY-1 trial |
Orkin__C_AIDS26_Poster_TUPEB099_AIDS1363_Tx.pdf |
| Efficacy and safety of single tablet BIC/LEN compared with B/F/TAF in maintaining virologic suppression
across age, sex, race, and geographic region subgroups in ARTISTRY-2 |
Cahn__P_AIDS26_Poster_TUPEB103_AIDS1367_Tx.pdf |
| Baseline and Week 48 Resistance Analyses in the Phase 3 ARTISTRY-1 Study Evaluating the BIC/LEN
Single-Tablet Regimen |
Margot__N_AIDS26_Poster_THPEB101_AIDS0705_Tx.pdf |
| E/C/F/TAF QD and HIV treatment other | |
| Long-term safety and efficacy of E/C/F/TAF in treatment naïve adolescents and virologically suppressed
children with HIV-1 |
Rakhmanina__N_AIDS26_Poster_WEPEB114_AIDS2004_Tx.pdf |
| Economic burden, hospitalization rates, and predictors of delayed diagnosis among US adults with HIV |
Cohen__J.P_AIDS26_Poster_THPEE534_AIDS1116_Tx.pdf |
| GS-3242 Q4-6M | |
| Resistance Profile of the HIV Integrase Strand Transfer Inhibitor GS-3242, a Potent Novel Long-Acting
Injectable INSTI in Clinical Development |
Hansen_D._AIDS26_Poster_THPEA026_Tx.pdf |
| HIV CURE | |
| Immune Biomarker Characterization of Amtabafusp (ABF), a Bispecific T-cell Engager, in a Phase 1b study
in People with HIV |
Zhang__L_AIDS26_Poster_WEPEB128_AIDS2018_Tx.pdf |
| Development of Long-Acting Antiretroviral Therapy for Sustained SIV Suppression in Rhesus Macaques |
Webb_GM_AIDS_2026_Poster_THPEA028.pdf |
| ISL/LEN QW | |
| Once-weekly oral Islatravir/Lenacapavir (ISL/LEN) versus daily standard-of-care therapy in virologically
suppressed adults with HIV-1: Week 48 results of the ISLEND-2 Phase 3 trial |
Colson_AIDS_2026_OAX1106LB.pdf |
| Once-weekly oral Islatravir/Lenacapavir (ISL/LEN) versus daily Bictegravir/Emtricitabine/Tenofovir
alafenamide (B/F/TAF) in virologically suppressed adults with HIV-1: Week 48 results of the ISLEND-1 Phase 3 trial |
Rockstroh_JK_ISLLEN_vs_BFTAF_Phase_3_Wk48_AIDS_2026_Oral_OAB1406LB.pdf |
| LEN for PrEP | |
| Experiences with twice-yearly lenacapavir for PrEP in the PURPOSE 1 open-label extension phase |
Nkosi_AIDS_2026_OAD0802.pdf |
| Endorsement and anticipated challenges to adopting twice-yearly lenacapavir for HIV pre-exposure
prophylaxis (PrEP) among cisgender men who have sex with men: Qualitative insights from the PURPOSE 2 trial |
Meanley_AIDS_2026_OAD0803.pdf |
| Zero HIV acquisitions with twice-yearly subcutaneous lenacapavir for PrEP during 52 weeks of open-label
extension in PURPOSE 1 |
Kiwanuka_N_AIDS_2026_Oral_OAC2802.pdf |
| High Efficacy of Twice-Yearly Subcutaneous Lenacapavir for PrEP Through 52 Weeks of Open-Label Extension
in PURPOSE 2 |
Losso_MH_AIDS_2026_OAC2806LB.pdf |
| Modeling Strategies to Maximize PrEP Impact in the United States with Twice-Yearly Lenacapavir |
Moore__M_AIDS26_Poster_TUPEC162_AIDS1425_Px.pdf |
| Genotypic data from participants screened for the PURPOSE 1 and PURPOSE 2 studies demonstrate low levels
of overall circulating resistance and no phenotypic resistance to lenacapavir |
Cox__S_AIDS26_Poster_TUPEC178_AIDS1441_Px.pdf |
| Favorable Tolerability of Lenacapavir for PrEP Administered at Participant-Chosen Anatomic Sites in
PURPOSE 1 and PURPOSE 2 |
Brites__C_AIDS26_Poster_TUPEC184_AIDS1447_Px.pdf |
| LEN for
PrEP & PrEP LANDSCAPE |
|
| Perceptions, Preferences and Unmet Need for PrEP: Results from a multi-country survey |
Charbonnier__J._AIDS26_Poster_THPEC173_Px.pdf |
| Optimizing STI testing frequency among pre-exposure prophylaxis users: implications for long-acting HIV
prevention in the real-world setting |
Tao__L_AIDS26_Poster_THPEC190_AIDS0792_Px.pdf |
| Integrating gender-affirming hormone therapy with twice-yearly subcutaneous lenacapavir for HIV
prevention: Longitudinal qualitative insights from transgender and nonbinary PURPOSE 2 participants |
Meanley__S_AIDS26_Poster_THPED306_AIDS0908_Px.pdf |
| LEN/TAB/ZAB Q6M | |
| Efficacy and safety of twice-yearly lenacapavir, teropavimab, and zinlirvimab as an HIV-1 treatment for
up to 104 weeks |
McMahon_JH_LENTABZAB_Phase_2_Wk104_AIDS_2026_Oral_OAB14.pdf |
Selected Gilead-supported abstracts
| B/F/TAF QD | |
|---|---|
| Rapid Telehealth-Enabled Antiretroviral Re-Initiation for Re-linkage to HIV Care: Interim findings from
the multisite ACCELERATE Study |
Rifi_R_AIDS_2026_Poster_TUPEE486.pdf |
| Virologic outcomes of B/F/TAF in PWH with Resistance to Antiviral Agents Exceeding one Component |
Wolf__E_AIDS26_Poster_THPEB129_AIDS0733_Tx.pdf |
| HIV-Prevention | |
| Multilevel social influences on PrEP modality choice and adherence among a subset of persons enrolled in
HPTN083, an international injectable PrEP trial |
Chen_Y_AIDS_2026_Oral_OAD0805.pdf |
| Meeting Transgender-Specific Needs: Service Acceptance and Identified Needs Among Thai Trans Women
Engaging in Substance Use or Chemsex (iT-REX Study) |
Hiransuthikul__A_AIDS26_Oral_OAD1803_AIDS0427_PxTx.pdf |
| Back to PrEP à Porter: Addressing Lost to Follow Up participants in a Community-Based Multidisciplinary
PrEP Implementation Strategy for Trans Women in Paris |
Pipitone__F_AIDS26_Oral_OAC1905_AIDS0402_Px.pdf |
| Implementing twice-yearly lenacapavir within public health PrEP services in Brazil: the ImPrEP
LEN-Brasil study |
Grinsztejn_B_AIDS_2026_Poster_LB53.pdf |
| Healthcare touchpoints preceding new HIV diagnoses among privately insured people with psychiatric and
substance use disorders in the U.S., 2003-2023 |
Bunting__S_AIDS26_Poster_TUPEC168_AIDS1431_PxTx.jpg |
| Rates and predictors of HIV pre-exposure prophylaxis discontinuation by administration schedule in the
Italian PrIDE cohort (EPI-PrEP Study) |
Mazzotta__V_AIDS26_Poster_TUPEC190_AIDS1453_Px.pdf |
| "I Truly Felt Like a Woman": Impact of Integrated Gender-Affirming Care on Acceptability of PrEP à
Porter, a Community-Based Multidisciplinary PrEP Implementation Strategy for Trans Women in Paris |
Pipitone_F_AIDS_2026_Poster_TUPED306.pdf |
| Estimating counterfactual background HIV incidence and cabotegravir efficacy versus a counterfactual
placebo in HPTN 083 using Bayesian modeling |
Dong_TQ_AIDS_2026_Poster_WEPEC190.pdf |
| Exploring barriers and facilitators to pharmacy-based HIV pre-exposure prophylaxis |
Lam_JT_AIDS_2026_Poster_WEPED318.pdf |
| "You Take What I Take, so You're Dead": External and Internal HIV Stigma in Migrant Transfeminine
Communities in Paris in the Age of PrEP |
Pignedoli_C_AIDS_2026_Poster_WEPED353.pdf |
| A statewide evaluation of the implementation of pharmacist-initiated HIV pre-exposure prophylaxis in
California |
Hunter_L._A._AIDS26_Poster_WEPEE455_Px.pdf |
| Suboptimal adherence to HIV pre-exposure prophylaxis across administration schedules: evidence from the
Italian PrIDE cohort (EPI- PrEP Study) |
Mazzotta__V_AIDS26_Poster_THPEC178_AIDS0780_Px.pdf |
| Co-production in HIV Prevention Research: Testing Equitable Collaboration Between Academic and Community
Leadership in the PrEP-Position Study |
Strachan_S_AIDS_2026_Poster_THPED364.pdf |
| HIV treatment other | |
| IL-15 Superagonist N-803, With or Without bNAbs, Induces Temporary Reduction and Transcriptional
Activation of the Intact HIV Reservoir |
Scheck_R_AIDS_2026_Oral_OAA1502.pdf |
| Risk of fracture with contemporary antiretrovirals within the RESPOND Consortium |
Neesgaard__B_AIDS26_Poster_TUPEB076_AIDS1340_Tx.pdf |
| HIV self-testing as a strategy to improve testing access among MSM and TSM in rural Switzerland |
Eggenberger_M_AIDS_2026_Poster_TUPEC225.pdf |
| Mucosal NK cells are associated with viral control during acute HIV-1 infection |
Phuang-Ngern_Y_AIDS_2026_Poster_WEPEA017.pdf |
| Mental Health as a Psychosocial Determinant of HIV Care Engagement and Viral Suppression among Black
Sexual and Gender Minorities living with HIV in Washington D.C. |
Oke_T_AIDS_2026_Poster_THPED422.pdf |
| Association between integrase inhibitors (INSTIs) and tenofovir alafenamide (TAF) and moderate chronic
kidney disease (CKD) in the RESPOND HIV cohort collaboration |
Greenberg__L_AIDS26__EP056_AIDS0040_Tx.pdf |
Publikationen vom IAS Kongress 2026
|
CABOTEGRAVIR + RILPIVIRINE Long-acting for treatment |
|
|
High acceptability and persistence of long-acting injectable cabotegravir/rilpivirine treatment in Australian primary care: early real-world implementation data from people living with HIV and healthcare workers* B. Eu et al. - In-person poster exhibition |
|
|
Real-world acceptability and experiences of long-acting injectable cabotegravir and rilpivirine: client perspectives and experiences* K.Alford et al. - In-person poster exhibition |
|
|
Acceptability and experience of long-acting injectable cabotegravir and rilpivirine in people with HIV and cognitive impairment* K.Alford et al. - In-person poster exhibition |
|
|
Comparable virologic effectiveness with long-acting cabotegravir + rilpivirine vs. daily bictegravir/emtricitabine/tenofovir alafenamide in the US-based OPERA Cohort Ricky K. Hsu et al. - In-person poster exhibition |
|
|
Resuppression and resistance after confirmed virologic failure among women on CAB+RPV LA in the OPERA Cohort Jessica Altamirano et al. - In-person poster exhibition |
|
|
High virologic suppression among individuals on cabotegravir + rilpivirine long-acting with viral loads ≥50 copies/mL regardless of body mass index in the OPERA Cohort Carl Millner et al. - In-person poster exhibition |
|
|
DTG/3TC-based regimens |
|
|
In VOGUE: DTG/3TC 2-drug regimen is non-inferior to BIC/FTC/TAF 3-drug regimen in a randomized trial in adults with HIV naive to treatment Jade Ghosn et al. - Oral presentation |
|
|
Long-term efficacy, safety and persistence of dolutegravir/lamivudine vs. bictegravir/emtricitabine/tenofovir alafenamide among virologically suppressed adults-results from the 144-week observational extension phase of the DYAD study* Charlotte-Paige Rolle et al. - In-person poster exhibition |
|
|
Incidence and outcomes of AIDS-defining illnesses after dolutegravir/lamivudine initiation in advanced HIV in the DOLCE Study* Pedro Cahn et al. - In-person poster exhibition |
|
|
No reactivation of Hepatitis B in African patients on a tenofovir free regimen for the treatment of HIV: results from the switch to DTG/3TC (Sungura) study* Loice Achieng Ombajo et al. - In-person poster exhibition |
|
|
The body composition signature of switching to BIC/FTC/TAF or DTG/3TC over 96 weeks* S. Di Gregorio et al. - Oral Presentation |
|
|
The impact of archived HIV-1 drug resistance on maintenance of virologic suppression through Week 48 in children aged 2 to <15 years receiving DTG/3TC: PENTA-21 intensive pharmacokinetic sub-study* Ruolan Wang et al. - Oral Presentation |
|
|
Who’s in VOGUE: a head‑to‑head clinical trial of dolutegravir/lamivudine (DTG/3TC) versus bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) in adults naive to antiretroviral therapy (ART), including those with high viral loads Federico Pulido et al. - In-person poster exhibition |
|
|
Pooled analysis of on-study viremic events (VEs) and outcomes for dolutegravir + lamivudine (DTG+3TC) and comparator 3-drug regimens (3DRs) in clinical trials of people with HIV-1 Pedro Cahn et al. - In-person poster exhibition |
|
|
Pipeline |
|
|
Participants report positive experiences switching from subcutaneous to intravenous lotivibart (LVB, N6LS, VH3810109) and cabotegravir long-acting injections for HIV-1 treatment in EMBRACE study Cassidy Gutner et al. - In-person poster exhibition |
|
|
Other HIV-related data |
|
|
Complex support needs, adherence challenges and interest in long-acting HIV treatment among Trans, Non-Binary, and Gender-Diverse people living with HIV: findings from the coproduced ‘Ask Us Europe’ survey* M. Devonald et al. - In-person poster exhibition |
|
|
Interest of people living with HIV in Europe in future long-acting modalities: Ask Us Europe results* M. Devonald et al. - In-person poster exhibition |
|
*denotes ViiV-supported investigator led and collaborative studies
Diese Seite weiter empfehlen
